Xbrane Biopharma has raised gross proceeds of SEK170m ($15.6m) through a directed share issue, handing the firm the financial firepower to build up launch volume and inventory for its flagship Ximluci (ranibizumab) biosimilar version of Lucentis in Europe.
Investors Plump For Xbrane With EU Ranibizumab Launch Plans Near
Ximluci Biosimilar Launch Eyed Early In 2023, With Stada To Commercialize
Sweden’s Xbrane BioPharma has followed through on plans to tap the equity markets for cash to fuel the planned launch of its Ximluci (ranibizumab) biosimilar version of Lucentis in Europe.
More from Biosimilars
• By
As Sandoz continues development of its planned pembrolizumab biosimilar rival to Keytruda, the company has revealed plans to slim down its Phase III trial amid the latest moves from regulators towards streamlining clinical study requirements for biosimilar registration.
• By
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
• By
The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.
• By
Stelara originator J&J has been denied in its initial attempt to prevent Samsung Bioepis and ustekinumab biosimilar partner Sandoz from selling a private-label version of the product through a PBM in the US.